or Try an Advanced Search...

    Technical Analysis for LRMR - Larimar Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 6.21 2.14% 0.13
    LRMR closed down 4.7 percent on Wednesday, November 20, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LRMR trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 2.14%
    Slingshot Bearish Bearish Swing Setup 2.14%
    Lower Bollinger Band Walk Weakness 2.14%
    Wide Bands Range Expansion 2.14%
    Lower Bollinger Band Touch Weakness 2.14%
    Oversold Stochastic Weakness 2.14%
    Lower Bollinger Band Walk Weakness -2.66%
    Wide Bands Range Expansion -2.66%
    Lower Bollinger Band Touch Weakness -2.66%
    Oversold Stochastic Weakness -2.66%
    Older End-of-Day Signals for LRMR ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 1 hour ago
    Up 2% about 2 hours ago
    Up 1% about 3 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    Lower Bollinger Band Support about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    LRMR Chart by TradingView
    Basic chart:

    Profile

    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders

    Is LRMR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
    Oct 30 Larimar Therapeutics GAAP EPS of -$0.24 beats by $0.14
    Oct 30 Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
    Oct 16 Larimar initiated with bullish view at Oppenheimer on lead drug
    Oct 7 Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
    Oct 3 Larimar started at outperform by Wedbush on FA drug candidate
    Sep 19 Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
    Sep 12 Jones Research starts Larimar at Buy, cites lead asset nomlabofusp
    Aug 27 Larimar Therapeutics to Participate in Upcoming Investor Conferences
    Aug 7 Larimar Therapeutics GAAP EPS of -$0.34
    See more LRMR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.68
    52 Week Low 3.19
    Average Volume 747,655
    200-Day Moving Average 8.13
    50-Day Moving Average 7.29
    20-Day Moving Average 7.82
    10-Day Moving Average 7.72
    Average True Range 0.67
    RSI (14) 36.31
    ADX 25.71
    +DI 21.82
    -DI 32.49
    Chandelier Exit (Long, 3 ATRs) 7.49
    Chandelier Exit (Short, 3 ATRs) 7.93
    Upper Bollinger Bands 9.66
    Lower Bollinger Band 5.99
    Percent B (%b) 0.02
    BandWidth 46.89
    MACD Line -0.23
    MACD Signal Line 0.07
    MACD Histogram -0.3021
    Fundamentals Value
    Market Cap 266.95 Million
    Num Shares 43.9 Million
    EPS -0.60
    Price-to-Earnings (P/E) Ratio -10.13
    Price-to-Sales 0.00
    Price-to-Book 3.68
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.07
    Resistance 3 (R3) 7.13 6.87 6.91
    Resistance 2 (R2) 6.87 6.61 6.84 6.85
    Resistance 1 (R1) 6.47 6.46 6.34 6.41 6.79
    Pivot Point 6.21 6.21 6.14 6.18 6.21
    Support 1 (S1) 5.81 5.95 5.68 5.75 5.37
    Support 2 (S2) 5.55 5.80 5.52 5.31
    Support 3 (S3) 5.15 5.55 5.26
    Support 4 (S4) 5.09